AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The Business Research Company's Phesgo Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, February 6, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Is the Phesgo Market Set to Witness Substantial Growth?
Driven by a rising awareness of HER2-positive breast cancer, an expanding variety of HER2-targeted therapies, along with sizable pharmaceutical industry investments, government healthcare initiatives, and favorable reimbursement policies, the Phesgo market has demonstrated considerable annual growth in recent years. Moving from a sizeable $XX million in 2024, the market is envisaged to reach $XX million by 2025, growing at an impressive compound annual growth rate CAGR of XX%.
Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=20347&type=smp
Looking ahead, the Phesgo market is not showing any signs of slowing down. On the contrary, it is expected to display an even more impressive growth rate over the next years thanks to a host of contributing factors. The expanding biologics sector, growth in healthcare infrastructure, rising use of combination therapies, the growing preference for targeted therapies, a rising focus on patient-centered care, and an increasing focus on subcutaneous biologics are all expected to play a major part in pushing the market size even higher to an expected $XX million by 2029, at a CAGR of XX%.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/phesgo-global-market-report
What Drives The Phesgo Market Growth?
The key drivers behind the Phesgo market's significant growth are multifaceted. Among the foremost is the rising number of breast cancer incidents across various regions. Breast cancer, a type of cancer that begins in the milk ducts or lobules of the breasts, is increasing due to aging populations, lifestyle changes, genetic predisposition, environmental exposures, and hormonal influences. These factors significantly contribute to this health concern which has a knock-on effect on the demand for medications such as Phesgo. Delivering a convenient fixed-dose combination of pertuzumab and trastuzumab, Phesgo helps delay tumor growth and progression by targeting the HER2 protein.
A perfect illustration of this driver is evident in the alarmingly rising number of new breast cancer cases in the United States. According to a study by the American Cancer Society, there was a substantial increase from 300,590 in 2023 to 313,510 in 2024, stimulating a corresponding demand for effective treatments such as Phesgo.
Who Are The Key Players In The Phesgo Market?
Playing a pivotal role in the Phesgo market are major companies like F. Hoffmann-La Roche AG and Chugai Pharmaceutical Co. Ltd. These industry players have an influential part in shaping the market trends and contributing to its progress.
What Are The Emerging Trends In The Phesgo Market?
A key trend currently shaping the Phesgo market is the introduction of innovative therapies such as monoclonal antibody combination therapy. These therapies have the potential to significantly enhance the treatment efficacy and improve patient outcomes in oncology, thereby providing an even more compelling case for their use. An excellent illustration of this trend is Chugai Pharmaceutical's November 2023 launch of the Phesgo combination for Subcutaneous Injection MA, IN. This innovative treatment combines pertuzumab and trastuzumab, two monoclonal antibodies, with hyaluronidase to offer a highly effective treatment for HER2-positive breast cancer and advanced HER2-positive colorectal cancer.
How Is The Phesgo Market Segmented?
Understanding the Phesgo market also requires an accurate grasp of its segmentation. The market is divided into specific areas for a thorough exploration.
1 By Indication: Early Breast Cancer; Metastatic Breast Cancer
2 By Formulation: Subcutaneous Injection; Intravenous Infusion
3 By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors
4 By End User: Hospitals; Oncology Clinics; Home Healthcare
Regional Analysis Of Phesgo Market:
When studying the dynamics of regional markets, North America took the lead as the largest Phesgo market region in 2024. As we move forward, Asia-Pacific is expected to dominate as the fastest-growing region. The comprehensive Phesgo market report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Discover more exciting insights through similar reports by The Business Research Company.
Breast Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
Breast Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Breast Cancer Monoclonal Antibodies Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodie-global-market-report
About The Business Research Company
With an extensive collection of 15000+ reports spanning 27 industries across 60+ geographies, The Business Research Company has carved a distinct reputation for delivering comprehensive, data-intensive research and insights. With our team's rich secondary research experience, access to 1,500,000 datasets, and industry leaders' exclusive insights, we ensure you stay ahead in your industry.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
